- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07504458
Pivotale åpen fase 3 klinisk studie av QTX-2101 hos voksne pasienter med akutt promyelocytisk leukemi (QUATRO-APL)
En avgjørende åpen fase 3 klinisk studie som evaluerer effektiviteten og sikkerheten til QTX-2101 i kombinasjon med all-trans-retinsyre ved nydiagnostisert, lavrisiko akutt promyelocytisk leukemi
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Rekruttering
- University of Alabama at Birmingham (UAB)
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Sravanti Rangaraju, MD
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Vinod Pullarkat, MD
-
Irvine, California, Forente stater, 92612
- Rekruttering
- University of California, Irvine
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Kiran Naqvi, MD
-
Los Angeles, California, Forente stater, 90033
- Rekruttering
- USC Norris Comprehensive Cancer Center
-
Hovedetterforsker:
- Eric Tam, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Orange, California, Forente stater, 92868
- Rekruttering
- UCI Health - UCI Medical Center
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Kiran Naqvi, MD
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford University School of Medicine
-
Hovedetterforsker:
- Tian Yi Zhang, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30912
- Rekruttering
- Augusta University Medical Center
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Anand Jillella, MD
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- Rekruttering
- University of Kentucky Markey Cancer Center
-
Hovedetterforsker:
- Ayman Qasrawi, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Rekruttering
- University of Maryland Medical Center
-
Hovedetterforsker:
- Maria Baer, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- E-post: ClinicalTrials@QuetzalTx.com
-
Baltimore, Maryland, Forente stater, 21231
- Rekruttering
- Johns Hopkins Kimmel Cancer Center
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Gabriel Ghiaur, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Dale L Bixby, MD
-
-
New York
-
Buffalo, New York, Forente stater, 14203
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
Hovedetterforsker:
- Eunice Wang, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Montefiore Medical Center
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Aditi Shastri, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- University of North Carolina at Chapel Hill
-
Hovedetterforsker:
- Joshua Zeidner, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University Wexner Medical Center
-
Hovedetterforsker:
- Uma Borate, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon Research Institute at TriStar Centennial Medical Center
-
Hovedetterforsker:
- Steven Strickland, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Hovedetterforsker:
- Farhad Ravandi, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- Rekruttering
- University of Virginia Health
-
Hovedetterforsker:
- Daniel Reed, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
-
-
-
-
Bordeaux, Frankrike, 33000
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François Magendie
-
Hovedetterforsker:
- Pierre-Yves Dumas, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
La Tronche, Frankrike, 38700
- Rekruttering
- CHU Grenoble Alpes - Hôpital Michallon
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Martin Carre, MD
-
Nancy, Frankrike, 54500
- Rekruttering
- Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de Brabois
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Caroline Bonmati, MD
-
Nice, Frankrike, 06202
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1
-
Hovedetterforsker:
- Thomas Cluzeau, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Paris, Frankrike, 75010
- Rekruttering
- Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis
-
Hovedetterforsker:
- Pierre Fenaux, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Saint-Priest-en-Jarez, Frankrike, 42270
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital Nord
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Emmanuelle Tavernier-Tardy, MD
-
Strasbourg, Frankrike, 67000
- Rekruttering
- Hôpitaux Universitaires de Strasbourg
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Marie-Pierre Ledoux, MD
-
-
-
-
-
Roma, Italia, 00133
- Rekruttering
- Hospital Tor Vergata Roma
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Maria Teresa Voso, MD
-
Vicenza, Italia, 36100
- Rekruttering
- Azienda ULSS 8 Berica - Ospedale San Bortolo
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Maria Cristina Miggiano, MD
-
-
-
-
-
Cluj-Napoca, Romania, 400015
- Rekruttering
- Institutul Oncologic "Prof. Dr. Ion Chiricuță"
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Minhea Zdrenghea, MD
-
-
-
-
-
Badalona, Spania, 08916
- Rekruttering
- Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol
-
Hovedetterforsker:
- Susana Vives Polo, MD
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Olga Salamero Garcia, MD
-
Barcelona, Spania, 08041
- Rekruttering
- Hospital de la Santa Creu i Sant Pau
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Ana Garrido Diaz, MD
-
Cáceres, Spania, 10003
- Rekruttering
- Hospital Universitario San Pedro de Alcántara
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Juan Miguel Bergua Burgúes, MD
-
Málaga, Spania, 29010
- Rekruttering
- Hospital Regional Universitario de Málaga
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Alejandro Contento Gonzalo, MD
-
Oviedo, Spania, 33011
- Rekruttering
- Hospital Universitario Central de Asturias
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Maria Teresa Bernal Castillo, MD
-
Valencia, Spania, 46026
- Rekruttering
- Hospital Universitario y Politécnico La Fe
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Pau Montesinos Fernández, MD
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spania, 07120
- Rekruttering
- Hospital Universitari Son Espases
-
Ta kontakt med:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-post: ClinicalTrials@QuetzalTx.com
-
Hovedetterforsker:
- Andres Novo Garcia, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Informed Consent
- Participants must be between 18 and under 71 years of age
- Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)
- Participants must be classified as low- or intermediate-risk APL
- Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures
Exclusion Criteria
- Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG
- Participants who have central nervous system leukemia
- Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe
- Participants who are pregnant, breastfeeding, or unwilling to use contraception
- Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: QTX-2101
QTX-2101 (oral arsenic trioxide; ATO) All-trans-retinoic-acid (ATRA; oral) |
The experimental regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, QTX-2101 is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
|
Aktiv komparator: IV ATO
IV Arsenic Trioxide (ATO) All-trans-retinoic-acid (ATRA; oral) |
The comparator regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, IV ATO is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIII
Tidsramme: Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
Cmax is defined as the maximum observed plasma concentration following administration of [investigational product], determined from plasma concentration-time data. |
Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
|
Molecular complete remission (molecular CR) rate
Tidsramme: Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
mCR is defined as the absence of detectable PML-RARA fusion transcript in bone marrow assessed by a validated quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay .The mCR rate is defined as the proportion of participants achieving molecular remission at the specified assessment time point following induction and consolidation therapy. |
Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Å karakterisere hendelsesfri overlevelse (EFS) for QTX-2101/ATRA
Tidsramme: Vurdert i opptil 3 år etter første dose behandling, eller til behandlingssvikt (sykdomsprogresjon), død eller studiens avslutning, avhengig av hva som inntreffer først
|
Vurdert i opptil 3 år etter første dose behandling, eller til behandlingssvikt (sykdomsprogresjon), død eller studiens avslutning, avhengig av hva som inntreffer først
|
|
|
To characterize the safety and tolerability of QTX-2101/ATRA and IV ATO/ATRA
Tidsramme: Throughout approximately 10 months of study treatment
|
Treatment emergent adverse events |
Throughout approximately 10 months of study treatment
|
|
Area under the plasma concentration-time curve (AUC) of QTX-2101 for ASIII
Tidsramme: Up to 10 months
|
AUC is defined as the area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC₀-t) and/or extrapolated to infinity (AUC₀-∞), calculated using noncompartmental methods. |
Up to 10 months
|
|
To complete a model-based concentration QT relationship evaluation
Tidsramme: Up to 10 months
|
Time-matched difference in change from baseline in QTcF interval between active treatment and placebo, derived from triplicate 12-lead ECGs at each post-dose time point |
Up to 10 months
|
|
EORTC QLQ-C30 domain unit of measure and measurement tool
Tidsramme: Up to 10 months
|
Change from baseline in EORTC QLQ-C30 global health status (0-100 scale) |
Up to 10 months
|
|
EQ-5D-5L domain unit of measure and measurement tool
Tidsramme: Up to 10 months
|
Change from baseline in EQ-5D-5L index score (0-100) |
Up to 10 months
|
|
Overall Survival
Tidsramme: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
OS is defined as the time from randomization to death from any cause. Participants who are alive at the time of analysis will be censored at the date last known to be alive. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
|
Event Free Survival (EFS)
Tidsramme: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
EFS is defined as the time from randomization to the first occurrence of any of the following events: failure to achieve hematologic or molecular remission, relapse (hematologic or molecular), or death from any cause. Participants without an event at the time of analysis will be censored at the date of last adequate disease assessment. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer etter histologisk type
- Leukemi, myeloid
- Leukemi, Myeloid, Akutt
- Hemic og lymfatiske sykdommer
- Neoplasmer
- Leukemi
- Hematologiske neoplasmer
- Hematologiske sykdommer
- Leukemi, promyelocytisk, akutt
- Organiske kjemikalier
- Retinoider
- Karotenoider
- Polyener
- Alkenes
- Hydrokarboner, acyklisk
- Hydrokarboner
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Pigmenter, biologisk
- Biologiske faktorer
- Uorganiske kjemikalier
- Diterpenes
- Oksider
- Oksygenforbindelser
- Vitamin A.
- Arsenicals
- Arsen trioksid
- Tretinoin
Andre studie-ID-numre
- QTX-2101-301
- 2025-524810-28-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .